Phenotypic and molecular characterization of quinolone resistance in mycobacterium abscessus subsp. bolletii recovered from postsurgical infections

Journal of Medical Microbiology

Volumn 61, Issue 1, 2012, Pages 115-125

  de Moura, Vinicius Calado Nogueira ^a   da Silva, Marlei Gomes ^b   Gomes, Karen Machado ^b   Coelho, Fábrice Santana ^c   Sampaio, Jorge Luiz Mello ^d   de Queiroz Mello, Fernanda Carvalho ^e   da Silva Lourenço, Maria Cristina ^f   de Amorim, Efigênia Lourdes Teixeira ^g   Duarte, Rafael Silva ^b  

^a UNIVERSIDADE DO ESTADO DO RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

^d Fleury   (Brazil)

^e Instituto de Doenças do Tórax   (Brazil)

^f Funda??o Oswaldo Cruz   (Brazil)

^g Sergio Franco Medicina Diagnóstica Laboratory   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ARGININE; ASPARTIC ACID; DNA TOPOISOMERASE (ATP HYDROLYSING); MOXIFLOXACIN; QUINOLONE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; BRAZIL; BROTH DILUTION; DNA SEQUENCE; ENTEROBACTERIACEAE; EPIDEMIC; GYRA BACTERIAL GENE; GYRB BACTERIAL GENE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM ABSCESSUS BOLLETII; MYCOBACTERIUM MASSILIENSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; STAPHYLOCOCCUS; STREPTOCOCCUS PNEUMONIAE; SURGICAL INFECTION;

ANTI-BACTERIAL AGENTS; BASE SEQUENCE; BRAZIL; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; PHENOTYPE; QUINOLONES; SEQUENCE ANALYSIS, DNA; SURGICAL WOUND INFECTION;

EID: 83755178104     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.034942-0     Document Type: Article

References (43)

1. Adékambi, T., Reynaud-Gaubert, M., Greub, G., Gevaudan, M. J., La Scola, B., Raoult, D. & Drancourt, M. (2004). Amoebal coculture of "Mycobacterium massiliense" sp. nov. from the sputum of a patient with hemoptoic pneumonia. J Clin Microbiol 42, 5493-5501.
2. Brown-Elliott, B. A. & Wallace, R. J., Jr (2002). Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 15, 716-746.
3. Brown-Elliott, B. A., Wallace, R. J., Jr, Crist, C. J., Mann, L. & Wilson, R. W. (2002). Comparison of in vitro activities of gatifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria. Antimicrob Agents Chemother 46, 3283-3285.
4. Cambau, E., Sougakoff, W., Besson, M., Truffot-Pernot, C., Grosset, J. & Jarlier, V. (1994). Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis 170, 479-483.
5. Cardoso, A. M., Martins de Sousa, E., Viana-Niero, C., Bonfim de Bortoli, F., Pereira das Neves, Z. C., Leão, S. C., Junqueira-Kipnis, A. P. & Kipnis, A. (2008). Emergence of nosocomial Mycobacterium massiliense infection in Goiás, Brazil. Microbes Infect 10, 1552-1557.
6. CLSI (2010). Performance Standards for Antimicrobial Susceptibility Testing, 20th informational supplement. CLSI document M100-S20. Wayne, PA: Clinical Laboratory and Standards Institute.
7. CLSI (2011). Susceptibility Testing of Mycobacteria, Nocardiae, and other Aerobic Actinomycetes, approved standard, 2nd edn. CLSI document M24-A2. Wayne, PA: Clinical Laboratory and Standards Institute.
8. Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S. & other authors (1998). Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537-544.
9. Danilchanka, O., Pavlenok, M. & Niederweis, M. (2008). Role of porins for uptake of antibiotics by Mycobacterium smegmatis. Antimicrob Agents Chemother 52, 3127-3134.
10. De Groote, M. A. & Huitt, G. (2006). Infections due to rapidly growing mycobacteria. Clin Infect Dis 42, 1756-1763.
11. Duarte, R. S., Lourenço, M. C. S., Fonseca, L. S., Leão, S. C., Amorim, E. L. T., Rocha, I. L. L., Coelho, F. S., Viana-Niero, C., Gomes, K. M. & other authors (2009). Epidemic of postsurgical infections caused by Mycobacterium massiliense. J Clin Microbiol 47, 2149-2155.
12. Guillemin, I., Cambau, E. & Jarlier, V. (1995). Sequences of conserved region in the A subunit of DNA gyrase from nine species of the genus Mycobacterium: phylogenetic analysis and implication for intrinsic susceptibility to quinolones. Antimicrob Agents Chemother 39, 2145-2149.
13. Guillemin, I., Jarlier, V. & Cambau, E. (1998). Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob Agents Chemother 42, 2084-2088.
14. Hernández, A., Sánchez, M. B. & Martínez, J. L. (2011). Quinolone resistance: much more than predicted. Front Microbiol 2, 1-6.
15. Höfling-Lima, A. L., de Freitas, D., Sampaio, J. L. M., Lea ̃ o, S. C. &Contarini, P. (2005). In vitro activity of fluoroquinolones against Mycobacterium abscessus and Mycobacterium chelonae causing infectious keratitis after LASIK in Brazil. Cornea 24, 730-734.
16. Ito, H., Yoshida, H., Bogaki-Shonai, M., Niga, T., Hattori, H. & Nakamura, S. (1994). Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob Agents Chemother 38, 2014-2023.
17. Lea ̃ o, S. C., Viana-Niero, C., Matsumoto, C. K., Lima, K. V. B., Lopes, M. L., Palaci, M., Hadad, D. J., Vinhas, S., Duarte, R. S. &other authors (2010). Epidemic of surgical-site infections by a single clone of rapidly growing mycobacteria in Brazil. Future Microbiol 5, 971-980.
18. Lea ̃ o, S. C., Tortoli, E., Euzé by, J. P. & Garcia, M. J. (2011). Proposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassified as Mycobacterium abscessus subsp. bolletii comb. nov., designation of Mycobacterium abscessus subsp. abscessus subsp. nov. and emended description of Mycobacterium abscessus. Int J Syst Evol Microbiol 61, 2311-2313.
19. Leysen, D. C., Haemers, A. & Pattyn, S. R. (1989). Mycobacteria and the new quinolones. Antimicrob Agents Chemother 33, 1-5.
20. Li, X. Z., Zhang, L. & Nikaido, H. (2004). Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegmatis. Antimicrob Agents Chemother 48, 2415-2423.
21. Liu, J., Takiff, H. E. & Nikaido, H. (1996). Active efflux of fluoroquinolones in Mycobacterium smegmatis mediated by LfrA, a multidrug efflux pump. J Bacteriol 178, 3791-3795.
22. Louw, G. E., Warren, R. M., Gey van Pittius, N. C., McEvoy, C. R. E., Van Helden, P. D. & Victor, T. C. (2009). A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrob Agents Chemother 53, 3181-3189.
23. Monego, F., Duarte, R. S. & Biondo, A. W. (2011). GyrA and gyrB gene mutation in ciprofloxacin-resistant Mycobacterium massiliense clinical isolates from Southern Brazil. Microb Drug Resist http://dx.doi.org/10.1089/mdr.2011.0047 (Epub ahead of print)
24. Montero, C., Mateu, G., Rodriguez, R. & Takiff, H. E. (2001). Intrinsic resistance of Mycobacterium smegmatis to fluoroquinolones may be influenced by new pentapeptide protein MfpA. Antimicrob Agents Chemother 45, 3387-3392.
25. Otto, T. D., Vasconcellos, E. A., Gomes, L. H. F., Moreira, A. S., Degrave, W. M., Mendonc ̧ a-Lima, L. & Alves-Ferreira, M. (2008). ChromaPipe: a pipeline for analysis, quality control and management for a DNA sequencing facility. Genet Mol Res 7, 861-871.
26. Pan, X. S., Ambler, J., Mehtar, S. & Fisher, L. M. (1996). Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother 40, 2321-2326.
27. Phillips, M. S. & von Reyn, C. F. (2001). Nosocomial infections due to nontuberculous mycobacteria. Clin Infect Dis 33, 1363-1374.
28. Reddy, A. K., Garg, P., Babu, K. H., Gopinathan, U. & Sharma, S. (2010). In vitro antibiotic susceptibility of rapidly growing nontuberculous mycobacteria isolated from patients with microbial keratitis. Curr Eye Res 35, 225-229.
29. Revel, V., Cambau, E., Jarlier, V. & Sougakoff, W. (1994). Characterization of mutations in Mycobacterium smegmatis involved in resistance to fluoroquinolones. Antimicrob Agents Chemother 38, 1991-1996.
30. Sampaio, J. L. (2010). Prokaryotic taxonomy rules and nomenclature changes in the Mycobacterium chelonae-abscessus group. Future Microbiol 5, 1457.
31. Scoper, S. V. (2008). Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy. Adv Ther 25, 979-994.
32. Stephan, J., Mailaender, C., Etienne, G., Daffé, M. and Niederweis, M. (2004). Multidrug resistance of a porin deletion mutant of Mycobacterium smegmatis. Antimicrob Agents Chemother 48, 4163-4170.
33. Stroman, D. W., Dajcs, J. J., Cupp, G. A. & Schlech, B. A. (2005). In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone. Surv Ophthalmol 50 (Suppl. 1), S16-S31.
34. Svetlíková, Z., Skovierová, H., Niederweis, M., Gaillard, J. L., McDonnell, G. & Jackson, M. (2009). Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs. Antimicrob Agents Chemother 53, 4015-4018.
35. Takiff, H. E., Salazar, L., Guerrero, C., Philipp, W., Huang, W. M., Kreiswirth, B., Cole, S. T., Jacobs, W. R., Jr & Telenti, A. (1994). Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 38, 773-780.
36. Viana-Niero, C., Lima, K. V. B., Lopes, M. L., Rabello, M. C. S., Marsola, L. R., Brilhante, V. C. R., Durham, A. M. &Lea ̃ o, S. C. (2008). Molecular characterization of Mycobacterium massiliense and Mycobacterium bolletii in isolates collected from outbreaks of infections after laparoscopic surgeries and cosmetic procedures. J Clin Microbiol 46, 850-855.
37. Von Groll, A., Martin, A., Jureen, P., Hoffner, S., Vandamme, P., Portaels, F., Palomino, J. C. & da Silva, P. A. (2009). Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother 53, 4498-4500.
38. Wallace, R. J., Jr, Brown, B. A. & Griffith, D. E. (1998). Nosocomial outbreaks/pseudo-outbreaks caused by nontuberculous mycobacteria. Annu Rev Microbiol 52, 453-490.
39. Wang, J. Y., Lee, L. N., Lai, H. C., Wang, S. K., Jan, I. S., Yu, C. J., Hsueh, P. R. & Yang, P. C. (2007). Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 59, 860-865.
40. Wolfson, J. S. & Hooper, D. C. (1985). The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother 28, 581-586.
41. Yew, W. W., Piddock, L. J. V., Li, M. S. K., Lyon, D., Chan, C. Y. & Cheng, A. F. B. (1994). In-vitro activity of quinolones and macrolides against mycobacteria. J Antimicrob Chemother 34, 343-351.
42. Yoshida, H., Bogaki, M., Nakamura, M. & Nakamura, S. (1990). Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother 34, 1271-1272.
43. Yoshida, H., Bogaki, M., Nakamura, M., Yamanaka, L. M. & Nakamura, S. (1991). Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother 35, 1647-1650.